Sun Pharma Q1 Results: Net profit declines 20% to ₹2,279 crore, revenue up 9%; check key details

The company reported a net profit of ₹2,835.6 crore for the April-June quarter of last year.

At 2:53 PM, shares of Sun Pharmaceutical Industries are trading 1.04% lower at ₹1,715.70 apiece on the NSE. Shares of Sun Pharmaceutical Industries have shown an increase of 2.28%.

The Mumbai-based pharma major witnessed an increase in revenue from operations by 9.47% to ₹13,851.4 crore for the first quarter compared with ₹12,652.75 crore in the year-ago period, the company said in a regulatory filing. Total income, which includes other income, rose to ₹14,315.8 crore from ₹13,185.3 crore in the corresponding period last year.

Total expenses for the quarter were reported at ₹10,325.1 crore, as against ₹9,761.8 crore in the previous year’s June quarter. This included cost of materials consumed, employee benefits, depreciation, and other expenses.

Profit before tax for the quarter came in at ₹3,172.8 crore, compared to ₹3,423.5 crore in Q1 FY25. Exceptional items stood at ₹818 crore for the quarter, while there were no exceptional items in the same quarter last year.

Earnings before interest, tax, depreciation and amortisation (EBITDA) for Q1 FY26 was reported at ₹4,302 crore, compared to ₹3,608 crore in Q1 FY25. EBITDA margin for the quarter stood at 31.06%, higher than 28.51% recorded a year earlier.

As mentioned in a regulator filing, the formulation sales of Sun Pharma in the US stood at ₹3,945 crore, contributing over 29.3% to the total consolidated revenue. Sales from Global Innovative Medicines reached ₹2,594 crore in Q1 FY26, marking a 16.9% year-on-year growth and accounting for 19.3% of the total consolidated sales during the quarter.

External sales of Active Pharmaceutical Ingredients (API) for the quarter were reported at ₹540.4 crore, registering a 9.3% increase. The API portfolio continues to support both the company’s formulation segment and customers across global markets.

Commenting on the quarterly performance, Dilip Shanghvi, Chairman and Managing Director of the Company, said, "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

Sun Pharma is a specialty generics company with operations across Innovative Medicines, Generics and Consumer Healthcare. It is the largest pharmaceutical company in India and has a notable presence in the US and global emerging markets. Around 20% of its sales come from its Innovative Medicines segment, which includes products in dermatology, ophthalmology, and onco-dermatology. The company operates through vertically integrated facilities and supplies medicines to over 100 countries. Its manufacturing network spans six continents and its workforce includes professionals from more than 50 countries.